Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

doi:10.1016/j.rec.2014.11.003

Ampliar

Pages 10-16 (January 2015)

Editorial
Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

Comentarios a la guía de práctica clínica de la ESC 2014 sobre el diagnóstico y tratamiento de la embolia pulmonar aguda

SEC Working Group for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism Expert Reviewers for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism SEC Clinical Practice Guidelines Committee

2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism

Rev Esp Cardiol. 2015;68:6410.1016/j.rec.2014.12.002

Stavros Konstantinides, Adam Torbicki, Giancarlo Agnelli, Nicolas Danchin, David Fitzmaurice, Nazzareno Galiè, J. Simon R. Gibbs, Menno Huisman, Marc Humbert†, Nils Kucher, Irene Lang, Mareike Lankeit, John Lekakis, Christoph Maack, Eckhard Mayer, Nicolas Meneveau, Arnaud Perrier, Piotr Pruszczyk, Lars H. Rasmussen, Thomas H. Schindler, Pavel Svitil, Anton Vonk Noordegraaf, Jose Luis Zamorano, Maurizio Zompatori

https://doi.org/10.1016/j.rec.2014.11.003

View PDF

Lea este artículo en español

Options

Other articles of interest

Statistics

3903 Total PDF

6612 Total HTML

Year/month	Html	Pdf	Total
2024 October	11	15	26
2024 September	71	29	100
2024 August	79	41	120
2024 July	38	20	58
2024 June	55	19	74
2024 May	70	17	87
2024 April	53	24	77
2024 March	61	29	90
2024 February	41	33	74
2024 January	53	19	72
2023 December	239	21	260
2023 November	22	37	59
2023 October	40	29	69
2023 September	29	15	44
2023 August	31	13	44
2023 July	39	56	95
2023 June	40	20	60
2023 May	46	19	65
2023 April	27	17	44
2023 March	30	11	41
2023 February	22	19	41
2023 January	24	22	46
2022 December	26	20	46
2022 November	39	21	60
2022 October	57	35	92
2022 September	32	31	63
2022 August	40	31	71
2022 July	27	21	48
2022 June	27	25	52
2022 May	37	25	62
2022 April	37	34	71
2022 March	41	45	86
2022 February	27	20	47
2022 January	23	26	49
2021 December	31	28	59
2021 November	22	29	51
2021 October	72	26	98
2021 September	34	25	59
2021 August	37	30	67
2021 July	42	20	62
2021 June	26	16	42
2021 May	43	19	62
2021 April	67	38	105
2021 March	84	31	115
2021 February	55	23	78
2021 January	44	5	49
2020 December	46	18	64
2020 November	27	15	42
2020 October	38	19	57
2020 September	46	14	60
2020 August	26	11	37
2020 July	22	9	31
2020 June	25	20	45
2020 May	41	17	58
2020 April	31	15	46
2020 March	103	12	115
2020 February	128	16	144
2020 January	44	18	62
2019 December	70	30	100
2019 November	53	16	69
2019 October	40	11	51
2019 September	76	36	112
2019 August	34	25	59
2019 July	29	68	97
2019 June	36	28	64
2019 May	32	13	45
2019 April	35	28	63
2019 March	49	24	73
2019 February	55	24	79
2019 January	68	32	100
2018 December	76	35	111
2018 November	46	27	73
2018 October	67	31	98
2018 September	35	21	56
2018 August	34	27	61
2018 July	59	19	78
2018 June	71	17	88
2018 May	64	28	92
2018 April	42	15	57
2018 March	58	11	69
2018 February	47	23	70
2018 January	48	18	66
2017 December	28	16	44
2017 November	31	15	46
2017 October	29	26	55
2017 September	26	13	39
2017 August	32	13	45
2017 July	28	7	35
2017 June	37	17	54
2017 May	37	21	58
2017 April	25	11	36
2017 March	28	20	48
2017 February	48	18	66
2017 January	67	14	81
2016 December	26	18	44
2016 November	40	24	64
2016 October	90	13	103
2016 September	142	39	181
2016 August	42	36	78
2016 July	82	37	119
2016 June	79	61	140
2016 May	47	59	106
2016 April	80	71	151
2016 March	59	76	135
2016 February	102	103	205
2016 January	119	119	238
2015 December	82	82	164
2015 November	91	144	235
2015 October	93	103	196
2015 September	102	96	198
2015 August	96	95	191
2015 July	134	115	249
2015 June	75	51	126
2015 May	108	63	171
2015 April	101	68	169
2015 March	114	74	188
2015 February	134	58	192
2015 January	257	163	420
2014 December	9	4	13

Este artículo solo puede leerse en pdf

References

[1]

M. Anguita, A. Fernández-Ortiz, F. Worner, A. Alonso, A. Cequier, J. Comín, et al.

La Sociedad Española de Cardiología y las guías de práctica clínica de la ESC: hacia una nueva orientación.

Rev Esp Cardiol., (2011), 64 pp. 795-796

http://dx.doi.org/10.1016/j.recesp.2011.05.013 | Medline

[2]

Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014 Aug 29 [in press]. pii: ehu283.

[3]

M. Righini, J. Van Es, P.L. Den Exter, P.M. Roy, F. Verschuren, A. Ghuysen, et al.

Age- adjusted d-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.

JAMA., (2014), 311 pp. 1117-1124

http://dx.doi.org/10.1001/jama.2014.2135 | Medline

[4]

P.D. Stein, S.E. Fowler, L.R. Goodman, A. Gottschalk, C.A. Hales, R.D. Hull, et al.

PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism.

N Engl J Med., (2006), 354 pp. 2317-2327

http://dx.doi.org/10.1056/NEJMoa052367 | Medline

[5]

S. Laporte, P. Mismetti, H. De’cousus, F. Uresandi, R. Otero, J.L. Lobo, et al.

Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

Circulation., (2008), 117 pp. 1711-1716

http://dx.doi.org/10.1161/CIRCULATIONAHA.107.726232 | Medline

[6]

S.Z. Goldhaber, L. Visani, M. De Rosa.

Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).

Lancet, (1999), 353 pp. 1386-1389

Medline

[7]

D. Aujesky, D.S. Obrosky, R.A. Stone, T.E. Auble, A. Perrier, J. Cornuz, et al.

Derivation and validation of a prognostic model for pulmonary embolism.

Am J Respir Crit Care Med., (2005), 172 pp. 1041-1046

http://dx.doi.org/10.1164/rccm.200506-862OC | Medline

[8]

D. Jiménez, D. Aujesky, L. Moores, V. Gómez, J.L. Lobo, F. Uresandi, et al.

Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.

Arch Intern Med., (2010), 170 pp. 1383-1389

http://dx.doi.org/10.1001/archinternmed.2010.199 | Medline

[9]

M. Righini, P.M. Roy, G. Meyer, F. Verschuren, D. Aujesky, G. Le Gal.

The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism.

J Thromb Haemost., (2011), 9 pp. 2115-2117

http://dx.doi.org/10.1111/j.1538-7836.2011.04469.x | Medline

[10]

D. Aujesky, P.M. Roy, F. Verschuren, M. Righini, J. Osterwalder, M. Egloff, et al.

Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.

Lancet., (2011), 378 pp. 41-48

http://dx.doi.org/10.1016/S0140-6736(11)60824-6 | Medline

[11]

G. Meyer, E. Vicaut, DanaysT, G. Agnelli, C. Becattini, J. Beyer-Westendorf, et al.

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

N Engl J Med., (2014), 370 pp. 1402-1411

http://dx.doi.org/10.1056/NEJMoa1302097 | Medline

[12]

S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, et al.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

N Engl J Med., (2009), 361 pp. 2342-2352

http://dx.doi.org/10.1056/NEJMoa0906598 | Medline

[13]

S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, et al.

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Circulation., (2014), 129 pp. 764-772

http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004450 | Medline

[14]

R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Büller, H. Decousus, A.S. Gallus, et al.

Oral rivaroxaban for symptomatic venous thromboembolism.

N Engl J Med., (2010), 363 pp. 2499-2510

http://dx.doi.org/10.1056/NEJMoa1007903 | Medline

[15]

H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, et al.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

N Engl J Med., (2012), 366 pp. 1287-1297

http://dx.doi.org/10.1056/NEJMoa1113572 | Medline

[16]

G. Agnelli, H.R. Büller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, et al.

Oral apixaban for the treatment of acute venous thromboembolism.

N Engl J Med., (2013), 369 pp. 799-808

http://dx.doi.org/10.1056/NEJMoa1302507 | Medline

[17]

H.R. Büller, H. Decousus, M.A. Grosso, M. Mercuri, S. Middeldorp, M.H. Prins, et al.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

N Engl J Med., (2013), 369 pp. 1406-1415

http://dx.doi.org/10.1056/NEJMoa1306638 | Medline

[18]

H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, et al.

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.

Eur Heart J., (2013), 34 pp. 2094-2106

http://dx.doi.org/10.1093/eurheartj/eht134 | Medline

[19]

Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas- Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 2014 Jul 6 [in press]. doi: 10.1016/j.thromres.2014.06.020.

[20]

P.M. Ridker, S.Z. Goldhaber, E. Danielson, Y. Rosenberg, C.S. Eby, S.R. Deitcher, et al.

PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

N Engl J Med., (2003), 348 pp. 1425-1434

http://dx.doi.org/10.1056/NEJMoa035029 | Medline

[21]

C. Kearon, J.S. Ginsberg, M.J. Kovacs, D.R. Anderson, P. Wells, J.A. Julian, et al.

Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

N Engl J Med., (2003), 349 pp. 631-639

http://dx.doi.org/10.1056/NEJMoa035422 | Medline

[22]

S. Husted, R. De Caterina, F. Andreotti, H. Arnesen, F. Bachmann, K. Huber, et al.

ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost., (2014), 111 pp. 781-782

http://dx.doi.org/10.1160/TH14-03-0228 | Medline

[23]

A. Amin, Y. Jing, J. Trocio, J. Lin, M. Lingohr-Smith, J. Graham.

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.

J Med Econ., (2014), 12 pp. 1-8

http://dx.doi.org/10.3111/13696990802648167 | Medline

[24]

M.L. Louzada, M. Carrier, A. Lazo-Langner, V. Dao, M.J. Kovacs, T.O. Ramsay, et al.

Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.

Circulation., (2012), 126 pp. 448-454

http://dx.doi.org/10.1161/CIRCULATIONAHA.111.051920 | Medline

A full list of the names of all authors are shown in the Appendix.